192 related articles for article (PubMed ID: 23370825)
1. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.
Bayraktar S; Gutierrez-Barrera AM; Lin H; Elsayegh N; Tasbas T; Litton JK; Ibrahim NK; Morrow PK; Green M; Valero V; Booser DJ; Hortobagyi GN; Arun BK
Clin Exp Metastasis; 2013 Jun; 30(5):631-42. PubMed ID: 23370825
[TBL] [Abstract][Full Text] [Related]
2. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
[TBL] [Abstract][Full Text] [Related]
3. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
[TBL] [Abstract][Full Text] [Related]
4. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH
World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760
[TBL] [Abstract][Full Text] [Related]
6. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
[TBL] [Abstract][Full Text] [Related]
7. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
8. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B
Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
Bayraktar S; Elsayegh N; Gutierrez Barrera AM; Lin H; Kuerer H; Tasbas T; Muse KI; Ready K; Litton J; Meric-Bernstam F; Hortobagyi GN; Albarracin CT; Arun B
Cancer; 2012 Mar; 118(6):1515-22. PubMed ID: 22009639
[TBL] [Abstract][Full Text] [Related]
11. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Arun B; Bayraktar S; Liu DD; Gutierrez Barrera AM; Atchley D; Pusztai L; Litton JK; Valero V; Meric-Bernstam F; Hortobagyi GN; Albarracin C
J Clin Oncol; 2011 Oct; 29(28):3739-46. PubMed ID: 21900106
[TBL] [Abstract][Full Text] [Related]
12. Mutations in
Fasching PA; Yadav S; Hu C; Wunderle M; Häberle L; Hart SN; Rübner M; Polley EC; Lee KY; Gnanaolivu RD; Hadji P; Hübner H; Tesch H; Ettl J; Overkamp F; Lux MP; Ekici AB; Volz B; Uhrig S; Lüftner D; Wallwiener M; Müller V; Belleville E; Untch M; Kolberg HC; Beckmann MW; Reis A; Hartmann A; Janni W; Wimberger P; Taran FA; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A; Hartkopf AD; Couch FJ
J Clin Oncol; 2021 May; 39(15):1619-1630. PubMed ID: 33780288
[TBL] [Abstract][Full Text] [Related]
13. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Atchley DP; Albarracin CT; Lopez A; Valero V; Amos CI; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
J Clin Oncol; 2008 Sep; 26(26):4282-8. PubMed ID: 18779615
[TBL] [Abstract][Full Text] [Related]
15. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
Neuhausen SL; Brummel S; Ding YC; Singer CF; Pfeiler G; Lynch HT; Nathanson KL; Rebbeck TR; Garber JE; Couch F; Weitzel J; Narod SA; Ganz PA; Daly MB; Godwin AK; Isaacs C; Olopade OI; Tomlinson G; Rubinstein WS; Tung N; Blum JL; Gillen DL
Breast Cancer Res; 2009; 11(5):R76. PubMed ID: 19843326
[TBL] [Abstract][Full Text] [Related]
17. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
18. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
19. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
Zhu Y; Wu J; Zhang C; Sun S; Zhang J; Liu W; Huang J; Zhang Z
Oncotarget; 2016 Oct; 7(43):70113-70127. PubMed ID: 27659521
[TBL] [Abstract][Full Text] [Related]
20. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
